2023. Primary analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma who progressed on or were intolerant to hedgehog inhibitors. SKIN The Journal of Cutaneous Medicine. 7, 2 (Mar. 2023), s177. DOI:https://doi.org/10.25251/skin.7.supp.177.